Monitoring for cytomegalovirus and Epstein-Barr virus infection in chronic lymphocytic leukemia patients receiving i.v. fludarabine-cyclophosphamide combination and alemtuzumab as consolidation therapy

Haematologica

Volumn 93, Issue 11, 2008, Pages 1758-1760

  Orlandi, Ester M ^a   Baldanti, Fausto ^a   Citro, Annalisa ^a   Pochintesta, Lara ^a   Gatti, Marta ^a   Lazzarino, Mario ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; CYCLOPHOSPHAMIDE; FLUDARABINE; GANCICLOVIR; VALACICLOVIR;

ADULT; CANCER COMBINATION CHEMOTHERAPY; CD4+ T LYMPHOCYTE; CHRONIC LYMPHATIC LEUKEMIA; COMBINATION CHEMOTHERAPY; CYTOMEGALOVIRUS; EPSTEIN BARR VIRUS; HUMAN; INFECTION RISK; LETTER; LYMPHOCYTE COUNT; VIRUS INFECTION; VIRUS LOAD;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; CYTOMEGALOVIRUS INFECTIONS; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; GENOME, VIRAL; HERPESVIRUS 4, HUMAN; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; VIDARABINE;

EID: 55549084915     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.13265     Document Type: Letter

References (12)

1. FrankDA, Mahajan S, Ritz J. Fludarabine-induced immunosuppression is associated with inhibition of STAT1 signalling. Nat Med 1999;5:444-7.
2. Eicchorst B, Bush R, Hopfinger G, Pasold R, Hensel M, Steinbrecher C, et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 2006;107:885-91.
3. Flinn JW, Neuberg DS, Grever MR, Dewald GW, Bennett JM, Paietta EM, et al. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukaemia: US Intergroup Trial E2997. J Clin Oncol 2007;25:793-8.
4. Catovsky D, Richards S, Matutes E, Oscier D, Dyer MJS, Bezares RF, et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukemia (the LRF CLL4 Trial): a randomised controlled trial. The Lancet 2007;370:230-9.
5. Lazzarino M, Orlandi E, Baldanti F, Furione M, Pagnucco G, Astori C, et al. The immunosuppression and potential for EBV reactivation of fludarabine combined with cyclophosphamide and dexamethasone in patients with lymphoproliferative disorders. Br J Haematol 1999;107:877-82.
6. Thronton PD, Bellas C, Santon A, Shah G, Pocock C, Wotherspoon AC, et al. Richter's transformation of chronic lymphocytic leukemia. The possible role of fludarabine and the Epstein-Barr virus in its pathogenesis. Leuk Res 2005;29:389-95.
7. Ng AP, Worth L, Chen L, Seymour JF, Prince HM, Slavin M, et al. Cytomegalovirus DNAemia and disease: incidence, natural history and management in settings other than allogeneic stem cell transplantation. Haematolgica 2005;90:1672-9.
8. Martin SI, Marty FM, Fiumare K, Treon SP, Gribben JG, Boden LR. Infectious complications associated with Alemtuzumab use for lymphoproliferative disorders. Clin Infect Dis 2006;43:16-24.
9. Baldanti F, Lilleri D, Gerna G. Monitoring human cytomegalovirus infection in transplant recipients. J Clin Virol 2008;41:237-41.
10. Eichhorst BF, Bush R, Schweighofer C, Wendtner CM, Emmerich B, Hallek M, et al. Due to low infection rate no routine anti-infective prophylaxis is required in younger patients with chronic lymphocytic leukaemia during fludarabine-based first line therapy. Br J Haematol 2006;136:63-72.
11. Hensel M, Kornacker M, Yammeni S, Egreer G, Ho AD. Disease activity and pre-treatment rather than hypogammaglobulinaemia are major risk factors for infectious complications in patients with chronic lymphocytic leukaemia. Br J Haematol 2003;122:600-6.
12. O'Brien S, Keating MJ, Mocarski ES. Updated guidelines on the management of Cytomegalovirus reactivation in patients with Chronic Lymphocytic Leukemia treated with Alemtuzumab. Clin Lymphoma Myeloma 2006;7:125-30.